River North 3-bedroom loft with private elevator: $1.6M
Price: $1,597,747
Listed: March 13, 2025
This three-bedroom, two-and-a-half bath loft in The Ronsley building features exposed brick walls and timber beams and is accessible by a private elevator. The home has 12-foot ceilings, floor-to-ceiling windows, hardwood floors, a home office space and a balcony. The ensuite bedrooms include motorized shades on the windows. The kitchen has a 10-foot island with quartzite countertops, Subzero and Wolf appliances, a pantry and additional cabinet storage. The primary suite features a spa-bath with an oversized shower, soaking tub, double sink vanity, water closet and a dressing area. A garage parking spot is available for purchase. The building features a 24/7 door staff and other amenities, including fitness rooms, a business center and a landscaped courtyard with grills and patio furniture.
Listing agent: Michael Rosenblum, Berkshire Hathaway HomeServices Chicago, 312-286-1634
River North 3-bedroom loft with private elevator: Living room
River North 3-bedroom loft with private elevator: Kitchen
River North 3-bedroom loft with private elevator: Dining area
River North 3-bedroom loft with private elevator: Office
River North 3-bedroom loft with private elevator: Primary bedroom
River North 3-bedroom loft with private elevator: Primary bathroom
River North 3-bedroom loft with private elevator: Second bedroom
River North 3-bedroom loft with private elevator: Second bathroom
River North 3-bedroom loft with private elevator: Third bedroom
River North 3-bedroom loft with private elevator: Laundry
River North 3-bedroom loft with private elevator: Terrace
River North 3-bedroom loft with private elevator: Deck
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
05-08-2025
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine
ST. PAUL, Minn., Aug. 5, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and children's hospital in Qatar, has been awarded a $100,000 G-Rex® Grant. Sidra Medicine's G-Rex® Grant will enable expeditious development, validation, and implementation of a G-Rex® centric CAR-T cell production platform. The G-Rex Grant will allow Sidra Medicine to perform the processes and preclinical development for a CD19 CAR-T cell therapy product that will initially be used in pediatric oncology settings. Sidra Medicine will also receive early access to the G-CART™ process currently in development at Cell Ready, the world's first and only G-Rex centric contract development and manufacturing organization (CDMO). The Grant will also support the implementation of fully closed system, semi-automated G-Rex production compliant with current Good Manufacturing Practices (cGMPs). Lastly, the Grant will support the technology transfer to Sidra Medicine's newly established GMP facility for qualification and implementation. "Sidra Medicine is a pioneering healthcare institution that has innovation weaved into the very core of its precision medicine program. Our GMP facility has been specifically set up to develop better treatment protocols for pediatric diseases including cancers, genetic and rare diseases. The G-Rex® Grant will play a key role in accelerating the readiness of our protocols, particularly for Sidra Medicine's pediatric oncology program. Our preliminary findings have already shown us that the G-Rex® method is outstanding in its simplicity and the unique T cell phenotype resulting from the cell culture. This methodology will allow us to implement an affordable, highly efficient G-Rex based cell manufacturing platform with the most suitable T cell phenotype, ultimately having a positive impact on pediatric patient care and cure," said Sara Deola, M.D., Ph.D., Research Investigator at Sidra Medicine. "We're eager to support the emerging Cell & Gene Therapy (CGT) industry in Qatar and the Middle East. By entering the field of CAR-T without any preconceived manufacturing notions and quickly gathering and reviewing G-Rex manufacturing data, Sidra Medicine quickly recognized the full array of advantages that our G-Rex centric manufacturing process offers relative to alternatives. Sidra Medicine's quick grasp of the technical and economic advantages of G-Rex relative to alternatives gives us confidence that this grant will set the stage for low cost and fully scalable CAR-T manufacturing in Qatar and the Middle East." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. ScaleReady's G-Rex Grant Program has now surpassed $40M of no-cost product commitments to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & Gene™. All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing. For more information about the G-Rex® Grant Program, please contact info@ For more information about LEAN Cell & Gene™, please use this link to register for the free event series. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Sidra Medicine Innovating Care. Transforming Lives From the heart of Qatar, Sidra Medicine, is a private, not-for-profit academic healthcare and research institution for women, children, and young people. Established by the Qatar Foundation for Education, Science, and Community Development, Sidra Medicine is committed to delivering exceptional patient and family-focused care, conducting innovative biomedical and clinical research, and providing a personalized journey of care and cure and precision medicine specifically for rare and genetic diseases. To access our specialised healthcare or international patient services, including pediatric care, women's health, and rare disease treatment or to book a consultation at one of our private clinics, please call +974 40033333 or visit our website at For more information, follow us on Facebook, Instagram, X and LinkedIn. View original content to download multimedia: SOURCE Bio-Techne Corporation
Yahoo
01-08-2025
- Yahoo
An Iconic Lake Winnipesaukee Estate Hits the Market for $13.5 Million
68 & 73 Sewall Road, Wolfeboro, NH — Where Luxury and Legacy Converge WOLFEBORO, N.H., Aug. 1, 2025 /PRNewswire/ -- Nestled along the coveted shores of Lake Winnipesaukee, a once-in-a-generation estate has officially come to market at 68 & 73 Sewall Road in Wolfeboro, New Hampshire. Listed at $13.5 million, this extraordinary waterfront compound spans over 4.5 acres with 247 feet of pristine shoreline, and 14,000+ square feet of combined living space, offering an unmatched blend of historical charm, modern luxury, and lakeside living. Shop Top Mortgage Rates Personalized rates in minutes A quicker path to financial freedom Your Path to Homeownership The primary residence at 68 Sewall Road is a 7,328 square foot waterfront estate, originally built in 1903 and masterfully reimagined to preserve its character while integrating world-class, modern finishes. Highlights include a Christopher Peacock-designed kitchen with a La Cornue range, Sub-Zero appliances, and a light-filled, south-facing dining room that opens to panoramic views of the lake and mountains. Six bedrooms, seven bathrooms, a grand great room, sauna, elevator, a four-season porch, and a state-of-the-art entertainment system complete the main home. A rare two-bay boathouse, fully restored in 2020, features luxurious living quarters above the water—an amenity no longer permitted for new builds. With a heated deck, radiant floor-heated bathroom, and top-of-the-line appliances, it redefines waterfront living. Across the road, 73 Sewall Road adds to the estate's versatility. This quintessential guest house offers four bedrooms, charming cottage aesthetics, and a fully outfitted car barn with lifts, radiant heat, and solar power. Recreational amenities include tennis and basketball courts, and the estate's total combined living space exceeds 14,000 sq ft with 13+ bedrooms and 14+ baths. Situated just half a mile from downtown Wolfeboro—America's oldest summer resort—the estate offers privacy without isolation. Sewall Road is renowned for its prestige, with properties in this enclave known to maintain and grow in value. From luxury finishes to exceptional amenities—and the benefit of no state income tax, no sales tax, and no tax on interest or dividends—this estate offers not just a home, but a lifestyle of unmatched distinction and enduring value. For more information, visit About Adam Dow and The Dow Group Adam Dow is the founder and leader of The Dow Group, New Hampshire's top-producing real estate team from 2015 through 2025. With over $1.5 billion in career sales, Adam and his team are trusted advisors in the luxury real estate market across the state. Known for their market expertise, innovative marketing, and white-glove service, The Dow Group delivers exceptional results for discerning buyers and sellers. To learn more, visit or or follow The Dow Group on Facebook, LinkedIn and Instagram. About PLACEPLACE is the real estate industry's only comprehensive business services and technology platform, designed to support the top real estate teams from any brokerage. From marketing and transaction management to technology and talent solutions, PLACE empowers top producers to scale their businesses efficiently and profitably. To learn more, visit or follow PLACE on Facebook, LinkedIn, and Instagram. View original content to download multimedia: SOURCE PLACE Inc.
Yahoo
28-07-2025
- Yahoo
Analyst Says ETH Could Hit $13K as Early as Q4, With $8K as Conservative Target
A popular pseudonymous crypto analyst on X known as "Wolf" has outlined a bullish roadmap for ether, predicting the second-largest cryptocurrency could hit $13,000 as early as the fourth quarter. While $13,000 is his optimistic scenario, Wolf's conservative target still places ETH above $8,000 — more than double its current level. In a chart-based post shared Friday, Wolf said he expects ether to continue rising sharply after reaching new all-time highs, though he warned of a 20%–25% correction following that breakout. He characterized this pullback as a 'final shakeout' before a longer-term rally resumes. Supporting the bullish outlook, institutional activity appears to be picking up. On-chain analysis service "Lookonchain" reported Monday that SharpLink Gaming (SBET), the Nasdaq-listed company that launched its ETH treasury strategy on June 2, had purchased another 77,210 ETH for roughly $295 million. The company now holds 438,017 ETH — worth approximately $1.69 billion — making it the largest publicly traded corporate holder of ether. The purchase follows SharpLink's appointment of former BlackRock executive Joseph Chalom as its new co-CEO last week, and came just three days after the company disclosed 567 ETH earned in staking rewards since it started accumulating ether. Meanwhile, Placeholder Ventures partner Chris Burniske noted that sentiment around ether has shifted dramatically over the past month. 'ETH went from most hated coin to darling of CT in ~5 weeks,' he wrote, referring to the crypto community on X. The token has gained roughly 73% since June 23. Ether is currently trading at $3,884, up 2% in the past 24 hours, according to CoinDesk data. Technical Analysis Highlights According to CoinDesk Research's technical analysis data model, ETH climbed from $3,771.30 to $3,888.72 between July 27 at 09:00 UTC and July 28 at 08:00 UTC, posting a 3.11% gain with a 4.91% intraday range. The token broke through key resistance around $3,837–$3,850 on strong volume, establishing a new support zone and positioning ETH for a potential advance toward $3,950–$4,000. In the final 60 minutes of the session, ETH rose from $3,890.61 to $3,898.38. A sharp spike from $3,876 to $3,898 occurred at 08:05 UTC on elevated volume, confirming strong institutional interest at breakout levels. Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.
